Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

PTC Therapeutics receives refuse to file letter from FDA for its DMD drug Translarna; agency says NDA is 'not sufficiently complete' to permit substantive review.

Advertisement

Related Content

Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.
Duchenne Development: Data Sharing May Enable Trials To Move Beyond Six-Minute Walk
FDA New Year’s Resolution: Guidances On Payor Communications, Biosimilarity
‘File Over Protest’ At US FDA: PTC To Pursue Rarely-Used Pathway For DMD Drug
Patient-Driven Drug Development Requires New Transparency Policies
Priority Review Politics: With Two Pending DMD Products, FDA Still Faces Community Anxiety
Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel